Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2403) 2403
Book Review (186) 186
Publication (69) 69
Newsletter (5) 5
Book Chapter (2) 2
Conference Proceeding (2) 2
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2254) 2254
humans (1878) 1878
carmustine - administration & dosage (1600) 1600
male (1351) 1351
female (1321) 1321
middle aged (1109) 1109
adult (1062) 1062
antineoplastic combined chemotherapy protocols - therapeutic use (960) 960
oncology (843) 843
aged (678) 678
chemotherapy (601) 601
animals (589) 589
combined modality therapy (575) 575
cyclophosphamide - administration & dosage (521) 521
carmustine - therapeutic use (515) 515
brain neoplasms - drug therapy (495) 495
melphalan - administration & dosage (424) 424
carmustine (421) 421
etoposide - administration & dosage (414) 414
carmustine - adverse effects (400) 400
antineoplastic combined chemotherapy protocols - adverse effects (386) 386
hematology (368) 368
cytarabine - administration & dosage (356) 356
adolescent (346) 346
treatment outcome (344) 344
antineoplastic combined chemotherapy protocols - administration & dosage (339) 339
transplantation, autologous (315) 315
vincristine - administration & dosage (313) 313
mice (305) 305
abridged index medicus (298) 298
cisplatin - administration & dosage (285) 285
glioma - drug therapy (271) 271
cancer (268) 268
transplantation (258) 258
antineoplastic agents - administration & dosage (246) 246
prognosis (242) 242
survival analysis (240) 240
doxorubicin - administration & dosage (234) 234
therapy (234) 234
rats (225) 225
survival rate (225) 225
antineoplastic agents, alkylating - administration & dosage (222) 222
bcnu (222) 222
time factors (222) 222
bone marrow transplantation (220) 220
prednisone - administration & dosage (220) 220
carmustine - pharmacology (216) 216
drug therapy, combination (209) 209
hematopoietic stem cell transplantation (209) 209
glioblastoma - drug therapy (203) 203
disease-free survival (199) 199
clinical neurology (191) 191
dose-response relationship, drug (182) 182
drug administration schedule (176) 176
follow-up studies (175) 175
cyclophosphamide (172) 172
retrospective studies (172) 172
bone-marrow transplantation (171) 171
radiotherapy (171) 171
remission induction (168) 168
immunology (167) 167
dacarbazine - administration & dosage (166) 166
antineoplastic agents - therapeutic use (164) 164
etoposide (163) 163
hodgkin disease - drug therapy (147) 147
malignant glioma (146) 146
survival (142) 142
brain neoplasms - radiotherapy (138) 138
hodgkin disease - therapy (138) 138
glioblastoma (136) 136
medicine & public health (134) 134
melanoma - drug therapy (132) 132
multiple myeloma - drug therapy (132) 132
pharmacology & pharmacy (127) 127
surgery (127) 127
child (126) 126
high-dose chemotherapy (126) 126
recurrence (126) 126
clinical trials as topic (124) 124
prospective studies (124) 124
antineoplastic agents, alkylating - therapeutic use (122) 122
care and treatment (122) 122
temozolomide (120) 120
brain neoplasms - pathology (119) 119
lymphoma, non-hodgkin - drug therapy (119) 119
brain neoplasms - surgery (118) 118
trial (118) 118
gliomas (116) 116
lymphoma, non-hodgkin - therapy (115) 115
salvage therapy (110) 110
non-hodgkins-lymphoma (108) 108
stem cells (108) 108
methotrexate - administration & dosage (107) 107
carmustine - toxicity (106) 106
cisplatin (106) 106
dexamethasone - administration & dosage (104) 104
brain neoplasms - therapy (103) 103
cyclophosphamide - therapeutic use (103) 103
neoplasm transplantation (100) 100
brain neoplasms - mortality (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2277) 2277
German (24) 24
Russian (22) 22
Spanish (21) 21
Japanese (18) 18
French (17) 17
Chinese (9) 9
Polish (9) 9
Italian (7) 7
Czech (2) 2
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
by Chiappella, Annalisa and Martelli, Maurizio and Angelucci, Emanuele and Brusamolino, Ercole and Evangelista, Andrea and Carella, Angelo Michele and Stelitano, Caterina and Rossi, Giuseppe and Balzarotti, Monica and Merli, Francesco and Gaidano, Gianluca and Pavone, Vincenzo and Rigacci, Luigi and Zaja, Francesco and D'Arco, Alfonso and Cascavilla, Nicola and Russo, Eleonora and Castellino, Alessia and Gotti, Manuel and Congiu, Angela Giovanna and Cabras, Maria Giuseppina and Tucci, Alessandra and Agostinelli, Claudio and Ciccone, Giovannino and Pileri, Stefano A and Vitolo, Umberto
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
by Cuccuini, Wendy and Briere, Josette and Mounier, Nicolas and Voelker, Hans-Ullrich and Rosenwald, Andreas and Sundstrom, Christer and Cogliatti, Sergio and Hirchaud, Edouard and Ysebaert, Loic and Bron, Dominique and Soulier, Jean and Gaulard, Philippe and Houlgatte, Remi and Gisselbrecht, Christian and Thieblemont, Catherine and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för immunologi, genetik och patologi and Molekylär och morfologisk patologi and Uppsala universitet
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy
by Shankar, Ananth and Hayward, Janis and Kirkwood, Amy and McCarthy, Keith and Hewitt, Martin and Morland, Bruce and Daw, Stephen
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma
by Rancea, Michaela and Will, Andrea and Borchmann, Peter and Monsef, Ina and Engert, Andreas and Skoetz, Nicole
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 8, pp. dju170 - dju170
This sixteenth biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials (RCTs) in the field... 
SURVIVAL | OUTCOMES | ONCOLOGY | STEM-CELL TRANSPLANTATION | CHOP PLUS RITUXIMAB | Hematologic Neoplasms - therapy | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Primary Myelofibrosis | Nitrogen Mustard Compounds - administration & dosage | Humans | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Melphalan - adverse effects | Vincristine - administration & dosage | Boronic Acids - administration & dosage | Carmustine - adverse effects | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Bortezomib | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Etoposide - administration & dosage | Nitrogen Mustard Compounds - adverse effects | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Melphalan - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
by Weihrauch, Martin R and Re, Daniel and Scheidhauer, Klemens and Ansén, Sascha and Dietlein, Markus and Bischoff, Stefanie and Bohlen, Heribert and Wolf, Jürgen and Schicha, Harald and Diehl, Volker and Tesch, Hans
Blood, ISSN 0006-4971, 11/2001, Volume 98, Issue 10, pp. 2930 - 2934
Residual mediastinal masses are frequently observed in patients with Hodgkin disease (HD) after completed therapy, and the discrimination between active tumor... 
Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Hodgkin Disease - pathology | Humans | Salvage Therapy | Transplantation, Autologous | Life Tables | Vinblastine - administration & dosage | False Positive Reactions | Mediastinal Neoplasms - therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Radiopharmaceuticals | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Diagnosis, Differential | Prednisone - administration & dosage | Dexamethasone - administration & dosage | False Negative Reactions | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | Bleomycin - administration & dosage | Mediastinal Neoplasms - diagnostic imaging | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Hodgkin Disease - therapy | Fibrosis | Fluorodeoxyglucose F18 | Tomography, Emission-Computed | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
by Paiva, Bruno and Vidriales, Maria-Belén and Cerveró, Jorge and Mateo, Gema and Pérez, Jose J and Montalbán, Maria A and Sureda, Anna and Montejano, Laura and Gutiérrez, Norma C and De Coca, Alfonso García and De Las Heras, Natalia and Mateos, Maria V and López-Berges, Maria C and García-Boyero, Raimundo and Galende, Josefina and Hernández, Jose and Palomera, Luis and Carrera, Dolores and Martínez, Rafael and De La Rubia, Javier and Martín, Alejandro and Bladé, Joan and Lahuerta, Juan J and Orfao, Alberto and San Miguel, Jesús F and GEM Grp Espanol MM PETHEMA and GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups and on behalf of the GEM (Grupo Espanol de MM)/PETHEMA (Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study groups
Blood, ISSN 0006-4971, 11/2008, Volume 112, Issue 10, pp. 4017 - 4023
Minimal residual disease (MRD) assessment is standard in many hematologic malignancies but is considered investigational in multiple myeloma (MM). We report a... 
RELAPSE | PREDICTS | POLYMERASE-CHAIN-REACTION | IMMUNOPHENOTYPIC EVALUATION | RISK | HIGH-DOSE MELPHALAN | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | PLASMA-CELLS | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Predictive Value of Tests | Flow Cytometry - methods | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Transplantation, Autologous | Cisplatin - administration & dosage | Neoplasm, Residual | Multiple Myeloma - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Multiple Myeloma - blood | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Survival Rate | Bleomycin - administration & dosage | Disease-Free Survival | Stem Cell Transplantation - methods | Aged | Mitomycin - administration & dosage | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur
by Geisler, Christian H and Kolstad, Arne and Laurell, Anna and Jerkeman, Mats and Räty, Riikka and Andersen, Niels S and Pedersen, Lone B and Eriksson, Mikael and Nordström, Marie and Kimby, Eva and Bentzen, Hans and Kuittinen, Outi and Lauritzsen, Grete F and Nilsson‐Ehle, Herman and Ralfkiær, Elisabeth and Ehinger, Mats and Sundström, Christer and Delabie, Jan and Karjalainen‐Lindsberg, Marja‐Liisa and Brown, Peter and Elonen, Erkki and Nordic Lymphoma Group and for the Nordic Lymphoma Group
British Journal of Haematology, ISSN 0007-1048, 08/2012, Volume 158, Issue 3, pp. 355 - 362
Mantle cell lymphoma ( MCL ) is a heterogenic non‐Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early – based on... 
autologous stem cell transplant | mantle cell lymphoma | high‐dose AraC | pre‐emptive therapy | rituximab | Pre-emptive therapy | Autologous stem cell transplant | Rituximab | High-dose AraC | Mantle cell lymphoma | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Mantle-Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Immunotherapy | Podophyllotoxin - administration & dosage | Female | Lymphoma, Mantle-Cell - drug therapy | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Disease-Free Survival | Lymphoma, Mantle-Cell - therapy | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Mantle-Cell - immunology | Aged | Hematopoietic Stem Cell Transplantation - methods | Carmustine - administration & dosage | Transplantation | Lymphomas | Stem cells | Index Medicus | Clinical trials | Autografts | Cell survival | Survival | stem cell transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
by Mercadal, S and Briones, J and Xicoy, B and Pedro, C and Escoda, L and Estany, C and Camós, M and Colomo, L and Espinosa, Í and Martínez, S and Ribera, J.M and Martino, R and Gutiérrez-García, G and Montserrat, E and López-Guillermo, A and Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) and On behalf of the Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB)
Annals of Oncology, ISSN 0923-7534, 5/2008, Volume 19, Issue 5, pp. 958 - 963
Aim: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young... 
Autologous stem-cell transplantation | Peripheral T-cell lymphoma | Prognosis | ALEMTUZUMAB | PROGNOSTIC-FACTORS | MARKER | NON-HODGKINS-LYMPHOMAS | peripheral T-cell lymphoma | GEL-TAMO EXPERIENCE | FRONT | MODEL | prognosis | FEATURES | ONCOLOGY | REAL CLASSIFICATION | autologous stem-cell transplantation | EXPRESSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Vincristine - administration & dosage | Adult | Female | Lymphoma, T-Cell, Peripheral - classification | Doxorubicin - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Neoplasms, Second Primary - epidemiology | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Vincristine - adverse effects | Lymphoma, T-Cell, Peripheral - surgery | Aged | Transplantation Conditioning | Peripheral Blood Stem Cell Transplantation | Doxorubicin - adverse effects | Carmustine - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Intensification treatment based on early FDG‐PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial
by Pardal, Emilia and Coronado, Mónica and Martín, Alejandro and Grande, Carlos and Marín‐Niebla, Ana and Panizo, Carlos and Bello, José Luis and Conde, Eulogio and Hernández, Miguel T and Arranz, Reyes and Bargay, Joan and González‐Barca, Eva and Pérez‐Ceballos, Elena and Montes‐Moreno, Santiago and Caballero, María Dolores
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 327 - 336
We conducted a multicentre, phase II study of interim positron emission tomography ( PET ) as a guide to risk‐adapted therapy in high‐risk patients with newly... 
fluorodeoxyglucose positron emission tomography | lymphoma | autologous stem cell transplantation | Fluorodeoxyglucose positron emission tomography | Lymphoma | Autologous stem cell transplantation | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Positron-Emission Tomography | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Radiopharmaceuticals | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Kaplan-Meier Estimate | Rituximab | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fluorodeoxyglucose F18 | Aged | Fluorine Radioisotopes | Peripheral Blood Stem Cell Transplantation | Carmustine - administration & dosage | PET imaging | Care and treatment | Lymphomas | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma
by García-Sanz, R and González-López, T.J and Vázquez, L and Hermida, G and Graciani, I.F and San Miguel, J.F
European Journal of Haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report... 
Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Hodgkin's lymphoma | dexamethasone | refractory disease | THERAPY | thalidomide | RECURRENT | transplantation | DISEASE | cyclophosphamide | VINBLASTINE | PATIENT | HEMATOLOGY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
by Josting, Andreas and Rudolph, C and Mapara, M and Glossmann, J.-P and Sienawski, M and Sieber, M and Kirchner, H.H and Dörken, B and Hossfeld, D.K and Kisro, J and Metzner, B and Berdel, W.E and Diehl, V and Engert, A
Annals of Oncology, ISSN 0923-7534, 01/2005, Volume 16, Issue 1, pp. 116 - 123
Background: We designed a dose- and time-intensified high-dose sequential chemotherapy regimen for patients with relapsed and refractory Hodgkin lymphoma (HD).... 
Sequential high-dose chemotherapy | Autologous transplantation | Hodgkin's lymphoma | INTENSIVE THERAPY | REGIMEN | RANDOMIZED TRIAL | ETOPOSIDE | autologous transplantation | RESCUE | BONE-MARROW TRANSPLANTATION | ONCOLOGY | DEXA-BEAM | DISEASE | SALVAGE THERAPY | sequential high-dose chemotherapy | STEM-CELL TRANSPLANTATION | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Injections, Subcutaneous | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Dexamethasone - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Infusions, Intravenous | Peripheral Blood Stem Cell Transplantation | Carmustine - administration & dosage | Granulocyte Colony-Stimulating Factor - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
by Bart Barlogie and Robert A. Kyle and Kenneth C. Anderson and Philip R. Greipp and Hillard M. Lazarus and David D. Hurd and Jason McCoy and Dennis F. Moore Jr and Shaker R. Dakhil and Keith S. Lanier and Robert A. Chapman and Jeana N. Cromer and Sydney E. Salmon and Brian Durie and John C. Crowley
Journal of Clinical Oncology, ISSN 0732-183X, 02/2006, Volume 24, Issue 6, pp. 929 - 936
Purpose Results of a prospective randomized trial conducted by the Intergroupe Francais du Myelome (IFM 90) indicated that autologous hematopoietic... 
STAGING SYSTEM | ALLOGENEIC TRANSPLANTATION | MAINTENANCE TREATMENT | THERAPY | PROGNOSTIC-FACTORS | ONCOLOGY | BONE-MARROW | AUTOLOGOUS TRANSPLANTATION | RANDOMIZED-TRIAL | STEM-CELL TRANSPLANTATION | MARROW TRANSPLANTATION | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | United States | Humans | Middle Aged | Clinical Protocols | Male | Transplantation, Autologous | Transplantation, Homologous | Multiple Myeloma - drug therapy | Treatment Failure | Bone Marrow Transplantation | Vincristine - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Multiple Myeloma - surgery | Prednisone - administration & dosage | Drug Administration Schedule | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Disease-Free Survival | Interferons - administration & dosage | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Multiple Myeloma - radiotherapy | Salvage Therapy - methods | Carmustine - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma
by Chen, Andy I and Leonard, Jessica T and Okada, Craig Y and Gay, Nathan D and Chansky, Kari and Fan, Guang and Dunlap, Jennifer B and Raess, Philipp W and Braziel, Rita M and Stentz, Alex and Maziarz, Richard T
Leukemia & Lymphoma, ISSN 1042-8194, 08/2018, Volume 59, Issue 8, pp. 1884 - 1889
High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin,... 
EPOCH-R | autologous transplant | Double hit lymphoma | ONCOLOGY | MYC | BCL2 | STEM-CELL TRANSPLANTATION | REARRANGEMENTS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Humans | Middle Aged | Etoposide - administration & dosage | Transplantation, Autologous | Treatment Outcome | Combined Modality Therapy | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gene Rearrangement | Vincristine - administration & dosage | Aged | Proto-Oncogene Proteins c-myc - genetics | Hematopoietic Stem Cell Transplantation - methods | Lymphoma, Large B-Cell, Diffuse - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Carmustine - administration & dosage | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights